Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KYMR

Kymera Therapeutics Inc

Apr 23 • 04:00PM ET

87.17

-1.60 -1.80 %

Healthcare • Biotechnology • USA • NASD

Peers: SRRK NRIX ARDX QURE KPTI CRNC RVNC MREO ONCT

| Held by: VTI VB IWM XBI VBK VXF IBB IWO SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.68	Insider Own	13.83%	Shs Outstand	81.32M	Perf Week	1.20%
Market Cap	7.12B	Forward P/E	-	EPS next Y	-4.16	Insider Trans	11.59%	Shs Float	70.35M	Perf Month	17.13%
Enterprise Value	6.35B	PEG	-	EPS next Q	-0.88	Inst Own	97.95%	Short Float	14.79%	Perf Quarter	19.79%
Income	-311.35M	P/S	181.50	EPS this Y	-0.41%	Inst Trans	8.04%	Short Ratio	14.58	Perf Half Y	49.47%
Sales	39.21M	P/B	4.49	EPS next Y	-12.15%	ROA	-22.89%	Short Interest	10.40M	Perf YTD	12.03%
Book/sh	19.42	P/C	8.39	EPS next 5Y	-5.58%	ROE	-25.78%	52W High	103.00 -15.37%	Perf Year	183.94%
Cash/sh	10.39	P/FCF	-	EPS past 3/5Y	-8.68% -3.19%	ROIC	-18.89%	52W Low	28.06 210.66%	Perf 3Y	150.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-5.74% 2.87%	Gross Margin	78.80%	Volatility	3.08% 4.08%	Perf 5Y	129.76%
Dividend TTM	-	EV/Sales	161.97	EPS Y/Y TTM	-24.00%	Oper. Margin	-881.27%	ATR (14)	3.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.47	Sales Y/Y TTM	-16.70%	Profit Margin	-794.06%	RSI (14)	54.61	Recom	1.05
Dividend Gr. 3/5Y	- -	Current Ratio	10.47	EPS Q/Q	-9.37%	SMA20	1.74%	Beta	2.16	Target Price	119.14
Payout	-	Debt/Eq	0.05	Sales Q/Q	-61.18%	SMA50	3.10%	Rel Volume	0.58	Prev Close	88.77
Employees	238	LT Debt/Eq	0.04	Earnings	Apr 30 BMO	SMA200	31.98%	Avg Volume	713.55K	Price	87.17
IPO	Aug 21, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.77% -80.92%	Trades		Volume	411,173	Change	-1.80%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Resumed	Barclays	Overweight	$133
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-03-25	Resumed	Guggenheim	Buy	$90
Oct-24-25	Reiterated	B. Riley Securities	Buy	$60 → $80
Oct-21-25	Initiated	Mizuho	Outperform	$81
Sep-18-25	Reiterated	H.C. Wainwright	Buy	$60 → $70
Sep-17-25	Initiated	Barclays	Overweight	$60
Sep-16-25	Initiated	RBC Capital Mkts	Outperform	$70
Jul-30-25	Resumed	B. Riley Securities	Buy	$60
Jul-03-25	Resumed	Morgan Stanley	Overweight	$70
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$79
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy	$60
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy	$51
May-20-25	Resumed	Stifel	Buy	$55
Mar-13-25	Initiated	Citigroup	Buy	$52
Dec-10-24	Initiated	BTIG Research	Buy	$60
Dec-06-24	Initiated	BMO Capital Markets	Market Perform	$55
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$57
Nov-18-24	Initiated	Stephens	Overweight	$65

Show Previous Ratings

Today 07:00AM	Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 (GlobeNewswire)
Apr-13-26 07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma (GlobeNewswire)
Apr-09-26 07:00AM	Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate (GlobeNewswire)
Mar-28-26 11:00AM	Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
07:00AM	Loading…
Mar-10-26 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-09-26 10:38PM	Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss (24/7 Wall St.)
Feb-28-26 01:32PM	Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 (MarketBeat)
Feb-27-26 09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
09:00AM	Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler (TipRanks)
Feb-26-26 05:03PM	Kymera Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:08PM	Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
09:55AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-26 07:19AM	Kymera Therapeutics Inc (KYMR) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:00AM	Loading…
Feb-24-26 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-19-26 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-14-26 01:03AM	Kymera Therapeutics Touts Once-Daily Oral Biologics-Like KT-621 at Guggenheim Conference (MarketBeat)
Feb-04-26 07:00AM	Kymera Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-30-26 10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Jan-15-26 11:35AM	Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside (Insider Monkey) -5.44%
Jan-13-26 07:00AM	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire)
Jan-12-26 12:00PM	Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why (Zacks)
Jan-06-26 07:00AM	Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Jan-05-26 01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
Jan-01-26 11:35AM	Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks (MarketBeat)
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 09:45AM	Share Offerings Prompt Huge Insider Buying in These 3 Biotechs (24/7 Wall St.)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
10:30AM	Loading…
Dec-12-25 10:30AM	Kymera's Eczema Drug Gets Fast Track Designation in the United States (Zacks)
Dec-11-25 04:01PM	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis (GlobeNewswire)
Dec-09-25 11:30PM	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering (GlobeNewswire) -7.87%
02:23PM	Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress (Insider Monkey)
10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
Dec-08-25 04:09PM	Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? (Investor's Business Daily) +41.55%
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:10PM	This Drugmaker's Stock Is Soaring Over 40% Monday (Investopedia)
01:07PM	Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:42AM	Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-05-25 04:01PM	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 (GlobeNewswire)
11:30AM	Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? (Zacks)
Dec-04-25 11:30AM	Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 07:33AM	Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
Nov-25-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Nov-24-25 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-04-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-03-25 07:26AM	Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-28-25 07:00AM	Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-27-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting (GlobeNewswire)
Oct-23-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-01-25 09:38AM	Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline (Zacks)
Sep-17-25 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses (GlobeNewswire)
Sep-16-25 12:30PM	Kymera initiated at Outperform on potential of lead skin drug (Investing.com)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-07-25 10:08AM	Why Kymera (KYMR) Could Be One of Biotech's Most Interesting Growth Stories? (Insider Monkey)
Sep-03-25 07:00AM	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary (GlobeNewswire) +6.41%
Aug-27-25 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-25 03:04AM	Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com) +5.81%
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.24%
07:00AM	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-25 09:23AM	GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up (Zacks)
09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result (GuruFocus.com)
Aug-06-25 10:00AM	CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Aug-04-25 07:00AM	Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-30-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 09:54AM	Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating (Insider Monkey)
Jul-09-25 06:02AM	Morgan Stanley Puts These 2 Stocks on Its Buy List Heres Why You Should Follow (TipRanks)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-28-25 04:16AM	Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer (Insider Monkey)
Jun-27-25 10:19AM	Kymeras partnerships with Sanofi and Gilead drive value (Investing.com)
Jun-26-25 11:56PM	Kymera Therapeutics Announces Pricing of $250 Million Public Offering (GlobeNewswire)
10:45AM	Kymera weakness a buying opportunity, says Stifel (TipRanks)
09:06AM	Morning Movers: General Mills dips following fourth quarter report (TipRanks)
08:40AM	KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update (Zacks)
Jun-25-25 04:05PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
01:04PM	Gilead eyes Kymeras adhesive cancer drug in $750m deal (Pharmaceutical Technology)
08:07AM	Kymera adds Gilead as research partner, while advancing new candidate with Sanofi (BioPharma Dive)
07:05AM	Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update (GlobeNewswire)
07:00AM	Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders (Business Wire)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-06-25 03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
Jun-05-25 04:16PM	Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial (Barrons.com) +7.68%
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
02:22AM	Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 10:29AM	Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response (Benzinga) +45.51%
07:44AM	Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
May-30-25 04:01PM	Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 (GlobeNewswire)
May-29-25 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.03%
May-19-25 12:15PM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference (GlobeNewswire)
May-10-25 07:00AM	Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks)

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Atlas Venture Fund X, LP	Shareholder	Apr 22 '26	Proposed Sale	88.07	88	7,750		Apr 22 04:52 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 22 '26	Proposed Sale	88.07	12	1,057		Apr 22 04:52 PM
JEREMY CHADWICK	Officer	Apr 22 '26	Proposed Sale	88.07	300	26,421		Apr 22 04:30 PM
Goodman Noah	Chief Business Officer	Apr 14 '26	Sale	90.00	1,347	121,230	50,195	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 14 '26	Option Exercise	32.16	5,251	168,887	66,453	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 15 '26	Option Exercise	43.50	1,300	56,550	62,502	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 14 '26	Sale	90.00	5,251	472,598	61,202	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 15 '26	Sale	90.00	1,300	117,000	61,202	Apr 16 06:30 PM
Booth Bruce	Director	Apr 14 '26	Option Exercise	14.18	4,159	58,975	4,159	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Option Exercise	14.18	2,200	31,196	2,200	Apr 16 06:16 PM
Booth Bruce	Director	Apr 14 '26	Sale	89.97	4,159	374,185	0	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Sale	90.10	3,135	282,464	674,956	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Sale	89.95	2,200	197,890	0	Apr 16 06:16 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 15 '26	Proposed Sale	89.87	385	34,600		Apr 15 04:51 PM
Atlas Venture Fund X, LP	Shareholder	Apr 15 '26	Proposed Sale	89.87	2,750	247,142		Apr 15 04:51 PM
JEREMY CHADWICK	Officer	Apr 15 '26	Proposed Sale	89.86	1,300	116,824		Apr 15 04:41 PM
Bruce Booth	Director	Apr 14 '26	Proposed Sale	88.53	24,000	2,124,720		Apr 14 05:19 PM
JEREMY CHADWICK	Officer	Apr 14 '26	Proposed Sale	88.53	5,251	464,871		Apr 14 04:37 PM
Goodman Noah	Chief Business Officer	Apr 09 '26	Option Exercise	21.05	2,500	52,625	61,806	Apr 10 04:45 PM
Goodman Noah	Chief Business Officer	Apr 09 '26	Sale	87.50	8,264	723,082	53,542	Apr 10 04:45 PM
Goodman Noah	Chief Business Officer	Apr 10 '26	Sale	87.35	2,000	174,700	51,542	Apr 10 04:45 PM
Noah Goodman	Officer	Apr 09 '26	Proposed Sale	87.35	11,611	1,014,221		Apr 09 04:28 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 01 '26	Option Exercise	29.64	14,640	433,930	75,842	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 31 '26	Option Exercise	29.64	7,600	225,264	68,802	Apr 01 07:00 PM
Ridloff Elena	Director	Mar 31 '26	Option Exercise	14.18	7,400	104,932	7,400	Apr 01 07:00 PM
Ridloff Elena	Director	Apr 01 '26	Option Exercise	14.18	4,600	65,228	4,600	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 01 '26	Sale	85.46	14,640	1,251,166	61,202	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 31 '26	Sale	85.38	7,600	648,882	61,202	Apr 01 07:00 PM
Ridloff Elena	Director	Mar 31 '26	Sale	85.37	7,400	631,739	0	Apr 01 07:00 PM
Ridloff Elena	Director	Apr 01 '26	Sale	85.42	4,600	392,922	0	Apr 01 07:00 PM
ELENA RIDLOFF	Director	Apr 01 '26	Proposed Sale	83.29	4,600	383,134		Apr 01 04:42 PM
JEREMY CHADWICK	Officer	Apr 01 '26	Proposed Sale	83.29	14,640	1,219,366		Apr 01 04:42 PM
JEREMY CHADWICK	Officer	Mar 31 '26	Proposed Sale	79.48	7,600	604,048		Mar 31 04:21 PM
ELENA RIDLOFF	Director	Mar 31 '26	Proposed Sale	79.48	7,400	588,152		Mar 31 04:19 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 23 '26	Option Exercise	29.64	84,400	2,501,616	152,452	Mar 25 05:15 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 25 '26	Option Exercise	29.64	24,727	732,908	85,929	Mar 25 05:15 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 23 '26	Sale	77.41	91,250	7,063,736	61,202	Mar 25 05:15 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 25 '26	Sale	80.26	24,727	1,984,554	61,202	Mar 25 05:15 PM
JEREMY CHADWICK	Officer	Mar 23 '26	Proposed Sale	77.91	115,977	9,035,768		Mar 23 04:36 PM
Esposito Pamela	Director	Mar 20 '26	Option Exercise	49.10	2,500	122,750	2,500	Mar 20 06:30 PM
Esposito Pamela	Director	Mar 20 '26	Sale	79.15	2,500	197,877	0	Mar 20 06:30 PM
PAMELA ESPOSITO	Director	Mar 20 '26	Proposed Sale	79.57	2,500	198,925		Mar 20 04:35 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 11 '26	Option Exercise	43.50	20,000	870,000	93,810	Mar 11 06:51 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 11 '26	Sale	83.30	25,758	2,145,673	68,052	Mar 11 06:51 PM
JEREMY CHADWICK	Officer	Mar 11 '26	Proposed Sale	84.58	25,758	2,178,612		Mar 11 04:40 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 04 '26	Sale	85.30	3,919	334,272	73,810	Mar 04 06:00 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 02 '26	Sale	88.93	2,039	181,322	77,729	Mar 04 06:00 PM
Gollob Jared	Chief Medical Officer	Mar 02 '26	Sale	88.93	5,613	499,148	122,029	Mar 04 06:00 PM
Gollob Jared	Chief Medical Officer	Mar 04 '26	Sale	85.30	4,895	417,521	117,134	Mar 04 06:00 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 02 '26	Sale	88.93	7,576	673,710	237,483	Mar 04 06:00 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 04 '26	Sale	85.30	4,895	417,521	232,588	Mar 04 06:00 PM
Booth Bruce	Director	Mar 02 '26	Sale	90.13	81,866	7,378,583	675,341	Mar 04 04:30 PM
Atlas Venture Opportunity Fund	Shareholder	Mar 02 '26	Proposed Sale	91.35	25,000	2,283,750		Mar 02 05:11 PM
Atlas Venture Fund X, LP	Shareholder	Mar 02 '26	Proposed Sale	91.35	200,000	18,270,000		Mar 02 05:11 PM
Gollob Jared	Officer	Mar 02 '26	Proposed Sale	90.10	10,613	956,231		Mar 02 05:08 PM
Chadwick Jeremy G	Officer	Mar 02 '26	Proposed Sale	90.10	6,206	559,161		Mar 02 05:07 PM
Jacobs Bruce N.	Officer	Mar 02 '26	Proposed Sale	90.10	12,576	1,133,098		Mar 02 05:06 PM
Mainolfi Nello	Chief Executive Officer	Feb 25 '26	Option Exercise	2.08	30,000	62,400	696,195	Feb 25 05:24 PM
Mainolfi Nello	Chief Executive Officer	Feb 25 '26	Sale	90.26	30,000	2,707,813	666,195	Feb 25 05:24 PM
Mainolfi Nello	Officer	Feb 25 '26	Proposed Sale	91.40	30,000	2,742,000		Feb 25 04:03 PM
Esposito Pamela	Director	Feb 20 '26	Option Exercise	49.10	2,500	122,750	2,500	Feb 20 05:30 PM
Esposito Pamela	Director	Feb 20 '26	Sale	87.31	2,500	218,270	0	Feb 20 05:30 PM
PAMELA ESPOSITO	Director	Feb 20 '26	Proposed Sale	86.50	2,500	216,250		Feb 20 04:28 PM
Esposito Pamela	Director	Jan 20 '26	Option Exercise	39.34	5,500	216,350	5,500	Jan 20 06:30 PM
Esposito Pamela	Director	Jan 20 '26	Sale	67.91	5,500	373,521	0	Jan 20 06:30 PM
PAMELA ESPOSITO	Director	Jan 20 '26	Proposed Sale	69.54	5,500	382,470		Jan 20 04:29 PM
Mainolfi Nello	Chief Executive Officer	Jan 05 '26	Option Exercise	32.07	3,118	99,994	666,195	Jan 06 04:40 PM
Mainolfi Nello	Chief Executive Officer	Dec 31 '25	Option Exercise	2.08	30,000	62,400	693,077	Dec 31 05:23 PM
Mainolfi Nello	Chief Executive Officer	Dec 31 '25	Sale	78.06	30,000	2,341,939	663,077	Dec 31 05:23 PM
Mainolfi Nello	Officer	Dec 31 '25	Proposed Sale	77.69	30,000	2,330,700		Dec 31 04:06 PM
Mainolfi Nello	Chief Executive Officer	Dec 17 '25	Option Exercise	38.53	2,595	99,985	663,077	Dec 17 06:07 PM
Esposito Pamela	Director	Dec 17 '25	Option Exercise	37.82	27,563	1,042,483	27,563	Dec 17 06:07 PM
Esposito Pamela	Director	Dec 17 '25	Sale	82.16	27,563	2,264,480	0	Dec 17 06:07 PM
PAMELA ESPOSITO	Director	Dec 17 '25	Proposed Sale	84.19	27,563	2,320,529		Dec 17 04:23 PM
Booth Bruce	Director	Dec 10 '25	Sale	91.73	229,809	21,080,724	686,477	Dec 12 06:37 PM
Booth Bruce	Director	Dec 11 '25	Sale	91.23	6,101	556,594	685,501	Dec 12 06:37 PM
Booth Bruce	Director	Dec 12 '25	Sale	91.04	678	61,725	685,393	Dec 12 06:37 PM
Atlas Venture Opportunity Fund	Director	Dec 12 '25	Proposed Sale	89.68	108	9,685		Dec 12 05:20 PM
Atlas Venture Fund X, L.P.	Director	Dec 12 '25	Proposed Sale	89.68	570	51,118		Dec 12 05:08 PM
Atlas Venture Opportunity Fund	Director	Dec 11 '25	Proposed Sale	87.81	976	85,703		Dec 11 05:13 PM
Atlas Venture Fund X, L.P.	Director	Dec 11 '25	Proposed Sale	87.81	5,125	450,026		Dec 11 05:01 PM
BAKER BROS. ADVISORS LP	Director	Dec 11 '25	Buy	86.00	2,005,813	172,499,918	7,955,916	Dec 11 04:19 PM
Atlas Venture Opportunity Fund	Director	Dec 10 '25	Proposed Sale	89.89	36,769	3,305,165		Dec 10 06:39 PM
Atlas Venture Fund X, L.P.	Director	Dec 10 '25	Proposed Sale	89.89	193,040	17,352,366		Dec 10 06:31 PM
Albers Jeffrey W.	Director	Dec 08 '25	Option Exercise	14.18	5,000	70,900	5,000	Dec 08 06:09 PM
Albers Jeffrey W.	Director	Dec 08 '25	Sale	89.76	5,000	448,823	0	Dec 08 06:09 PM
Mainolfi Nello	Chief Executive Officer	Dec 08 '25	Option Exercise	2.08	100,000	208,000	760,482	Dec 08 06:09 PM
Mainolfi Nello	Chief Executive Officer	Dec 08 '25	Sale	89.17	100,000	8,917,000	660,482	Dec 08 06:09 PM
Gollob Jared	Chief Medical Officer	Dec 08 '25	Option Exercise	5.33	49,307	262,806	159,299	Dec 08 06:09 PM
Gollob Jared	Chief Medical Officer	Dec 08 '25	Sale	88.67	49,307	4,371,833	109,992	Dec 08 06:09 PM
Mainolfi Nello	Officer	Dec 08 '25	Proposed Sale	89.17	100,000	8,917,000		Dec 08 06:05 PM
Jared Gollob	Officer	Dec 08 '25	Proposed Sale	66.62	49,307	3,284,832		Dec 08 06:03 PM
JEFFREY ALBERS	Director	Dec 08 '25	Proposed Sale	66.62	5,000	333,100		Dec 08 06:03 PM
Mainolfi Nello	Chief Executive Officer	Oct 29 '25	Option Exercise	2.08	30,000	62,400	690,482	Oct 29 05:19 PM
Mainolfi Nello	Chief Executive Officer	Oct 29 '25	Sale	60.99	30,000	1,829,737	660,482	Oct 29 05:19 PM
Mainolfi Nello	Officer	Oct 29 '25	Proposed Sale	61.68	30,000	1,850,400		Oct 29 04:03 PM
Gollob Jared	Chief Medical Officer	Oct 15 '25	Option Exercise	1.64	51,209	84,185	169,568	Oct 15 05:28 PM
Gollob Jared	Chief Medical Officer	Oct 15 '25	Sale	61.42	59,576	3,659,254	109,992	Oct 15 05:28 PM
Jared Gollob	Officer	Oct 15 '25	Proposed Sale	58.26	59,576	3,470,898		Oct 15 04:36 PM
Gollob Jared	Chief Medical Officer	Oct 13 '25	Option Exercise	1.66	1,473	2,448	121,473	Oct 14 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYMR

Kymera Therapeutics Inc

Upgrade your Finviz experience